AETHON THERAPEUTICS
Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with TCI of RAS, EGFR, and other cancer-associated mutations.
AETHON THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Product Research
Founded:
2022-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.aethontx.com
Total Employee:
11+
Status:
Active
Total Funding:
30 M USD
Technology used in webpage:
Google Maps Amazon U.S. Server Location Google Maps API Amazon Virginia Region CloudFront Invalid Certificate Dates
Similar Organizations
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Structure Therapeutics
Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Investors List
Apple Tree Partners
Apple Tree Partners investment in Series A - Aethon Therapeutics
NYU Langone Health
NYU Langone Health investment in Series A - Aethon Therapeutics
Official Site Inspections
http://www.aethontx.com Semrush global rank: 13.23 M Semrush visits lastest month: 78
- Host name: 181.0.153.160.host.secureserver.net
- IP address: 160.153.0.181
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Aethon Therapeutics"
Aethon Therapeutics - Crunchbase Company Profile
Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with …See details»
about – Aethon Therapeutics
1) The beacon: Aethon creates tumor-specific antigens so that the body’s immune system can find and fight tumors that otherwise would evade detection. 2) The hybrid and the workhorse: …See details»
people – Aethon Therapeutics
Christoph Rader, Ph.D. Chief Technology Officer. Christoph Rader is Chief Technology Officer at Aethon Therapeutics. Prior to joining the company, Christoph had a distinguished academic career at The Scripps Research …See details»
Aethon Therapeutics - LinkedIn
We are delighted to announce Christoph Rader, CTO at Aethon Therapeutics, will be speaking at the 4th Edition of The Antibody Series (Sept 4 - 6, 2024) on "Creating and targeting synthetic ...See details»
Aethon (Drug Discovery) - PitchBook
Jan 9, 2023 Information on valuation, funding, cap tables, investors, and executives for Aethon (Drug Discovery). Use the PitchBook Platform to explore the full profile.See details»
Apple Tree Partners | ATP and NYU Langone Health Launc...
Jan 9, 2023 For more information, visit www.aethontx.com. About ATP. Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in …See details»
Apple Tree Partners | Aethon Therapeutics Announces Co...
Apr 4, 2024 Co-founded by venture capital firm Apple Tree Partners with New York University cancer researchers Shohei Koide, Ph.D. and Benjamin G. Neel, M.D., Ph.D., Aethon unites …See details»
NYU Langone Health Researchers Launch Aethon Therapeutics …
Researchers from NYU Langone Health's Perlmutter Cancer Center – Shohei Koide, PhD and Benjamin G. Neel, MD, PhD – have co-founded Aethon Therapeutics with Apple Tree Partners …See details»
Aethon Therapeutics Announces Collaboration with Revolution …
Apr 4, 2024 Aethon Therapeutics, Inc., a biotechnology company discovering and developing novel antibody therapeutics designed to attack cancer cells in tandem with targeted covalent …See details»
ATP and NYU Langone Health Launch Aethon Therapeutics to …
Jan 9, 2023 For more information, visit www.aethontx.com. About ATP. Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in …See details»
ATP and NYU Langone Health Launch Aethon Therapeutics to …
Jan 9, 2023 For more information, visit www.aethontx.com. About ATP. Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in …See details»
Working at Aethon Therapeutics - Glassdoor
Glassdoor gives you an inside look at what it's like to work at Aethon Therapeutics, including salaries, reviews, office photos, and more. This is the Aethon Therapeutics company profile.See details»
Aethon Therapeutics Announces Collaboration with Revolution …
Apr 4, 2024 Aethon Therapeutics, Inc. today announced that it has entered into a collaboration agreement with Revolution Medicines, Inc., a clinical-stage oncology company developing …See details»
ATP and NYU Langone Health Launch Aethon Therapeutics to …
For Innovators. Getting your innovations out into the world and to the people that need them.See details»
‪Christoph Rader‬ - ‪Google Scholar‬
‪Chief Technology Officer, Aethon Therapeutics, Inc.‬ - ‪‪Cited by 14,910‬‬ - ‪Antibody Therapeutics‬ - ‪Antibody Engineering‬ - ‪Phage Display‬ - ‪Antibody-Drug Conjugates‬ - ‪Bispecific Antibodies‬See details»
ATP and NYU Langone Health Launch Aethon Therapeutics to
Jan 9, 2023 For more information, visit www.aethontx.com. About ATP. Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in …See details»
Aethon Therapeutics Announces Collaboration with Revolution …
Apr 4, 2024 Aethon will apply its proprietary HapImmuneâ„¢ platform to create novel antibodies that home in on cancer neoantigens generated by treatment with RAS inhibitorsSee details»
Aethon $30M series A round targets drug-based neoantigens
Jan 9, 2023 Aethon Therapeutics Inc. closed a $30 million series A round to develop a novel antibody-based therapeutic strategy for cancer, which relies on the concomitant use of small …See details»
news – Aethon Therapeutics
For more information, visit www.aethontx.com. About ATP Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in New York, …See details»